Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Strong Trading Volume – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw unusually-high trading volume on Wednesday . Approximately 5,162,483 shares traded hands during trading, an increase of 301% from the previous session’s volume of 1,287,501 shares.The stock last traded at $11.3648 and had previously closed at $11.05.

Analyst Upgrades and Downgrades

BAYRY has been the topic of a number of analyst reports. UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. DZ Bank upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm has a 50 day simple moving average of $11.28 and a 200-day simple moving average of $11.04. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The company has a market cap of $44.68 billion, a price-to-earnings ratio of -17.76, a PEG ratio of 3.57 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. The company had revenue of $15.73 billion during the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft had a positive return on equity of 17.74% and a negative net margin of 4.75%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, analysts predict that Bayer Aktiengesellschaft will post 1.24 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.